EUVIMEDEUVIMED entdecken
Crossref

Serum Netrin-1 and ultrasonographic hepatic steatosis severity in obese children and adolescents with metabolic dysfunction–associated steatotic liver disease: a preliminary study

Leyla Gizem Bolaç Özyılmaz, Ertuğrul İnan, Sevgi Özdemir Akgün, Safa Özyılmaz, Aydilek Dağdeviren Çakır, Ahmet Uçar

European Journal of Pediatrics · 2026

DOI: 10.1007/s00431-026-07566-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pediatrics, 2026. Verfasst von Leyla Gizem Bolaç Özyılmaz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. gizembol…. Hauptthemen laut MEDLINE: Netrin-1, Fatty Liver, Pediatric Obesity, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a frequent hepatic complication of pediatric obesity, yet non-invasive circulating biomarkers associated with ultrasonographic steatosis severity remain limited. Netrin-1 is an immunometabolic regulator implicated in obesity-related inflammation and lipid metabolism, but prospective pediatric data in MASLD are scarce. In this preliminary prospective case–control study, 44 children and adolescents with obesity-related MASLD and 44 age- and sex-matched healthy controls with normal BMI were enrolled. Hepatic steatosis was assessed by ultrasonography, and serum Netrin-1 concentrations were measured by ELISA. Associations with ultrasonographic steatosis grade were evaluated using regression analyses, and discriminatory performance for moderate-to-severe ultrasonographic steatosis, defined as grades 2–3, was explored by receiver operating characteristic (ROC) analysis. Serum Netrin-1 concentrations were significantly higher in children and adolescents with obesity-related MASLD than in healthy controls with normal BMI (633.9 vs 302.0 pg/mL; p < 0.001). Within the MASLD group, Netrin-1 concentrations were higher in participants with grade 2–3 steatosis than in those with grade 1 steatosis (828.9 vs 594.7 pg/mL; p < 0.001). Netrin-1 correlated positively with alanine aminotransferase ( ρ = 0.669; p < 0.001). ROC analysis showed good discriminatory performance for moderate-to-severe ultrasonographic steatosis (AUC 0.827; 95% CI 0.699–0.955). Conclusion : These preliminary findings suggest that serum Netrin-1 may represent an exploratory complementary biomarker candidate associated with ultrasonographic steatosis severity in pediatric MASLD. Larger multicenter studies including children and adolescents with obesity but without steatosis, together with quantitative imaging-based assessment, are required to validate these associations and determine the incremental clinical value of serum Netrin-1. What is Known: • Pediatric MASLD lacks validated non-invasive circulating biomarkers for assessing hepatic steatosis severity. • Netrin-1 is an immunometabolic mediator implicated in obesity-related inflammation and lipid metabolism, but pediatric data in MASLD are scarce. What is New: • In this preliminary prospective case–control study, serum Netrin-1 concentrations were higher in children and adolescents with obesity-related MASLD and were higher in those with grade 2–3 ultrasonographic steatosis than in those with grade 1 steatosis. • Serum Netrin-1 showed good exploratory discriminatory performance for moderate-to-severe ultrasonographic steatosis, suggesting that it may represent a complementary biomarker candidate requiring validation in larger independent pediatric cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Netrin-1Fatty LiverPediatric ObesityNon-alcoholic Fatty Liver DiseaseHumansMaleFemaleAdolescentChildProspective StudiesCase-Control StudiesBiomarkersUltrasonographySeverity of Illness IndexROC CurveEnzyme-Linked Immunosorbent Assay

Stichwörter der Autor:innen

AdolescentsBiomarkersChildrenHepatic steatosisMASLDNetrin-1

Substanzen

Netrin-1BiomarkersNTN1 protein, human

Autor:innen und Institutionen

  • Department of Pediatric Endocrinology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. gizembolac@gmail.com.
  • Department of Pediatric Endocrinology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
  • Department of Radiology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.

Zitieren

APA

Özyılmaz, L. G. B., İnan, E., Özdemir Akgün, S., Özyılmaz, S., Çakır, A. D., & Uçar, A. (2026). Serum Netrin-1 and ultrasonographic hepatic steatosis severity in obese children and adolescents with metabolic dysfunction–associated steatotic liver disease: a preliminary study. European Journal of Pediatrics. https://doi.org/10.1007/s00431-026-07566-2

Vancouver

Özyılmaz LGB, İnan E, Özdemir Akgün S, Özyılmaz S, Çakır AD, Uçar A. Serum Netrin-1 and ultrasonographic hepatic steatosis severity in obese children and adolescents with metabolic dysfunction–associated steatotic liver disease: a preliminary study. European Journal of Pediatrics. 2026. doi:10.1007/s00431-026-07566-2

BibTeX
@article{zylmaz2026,
  author = {Özyılmaz, Leyla Gizem Bolaç and İnan, Ertuğrul and Özdemir Akgün, Sevgi and Özyılmaz, Safa and Çakır, Aydilek Dağdeviren and Uçar, Ahmet},
  title = {Serum Netrin-1 and ultrasonographic hepatic steatosis severity in obese children and adolescents with metabolic dysfunction–associated steatotic liver disease: a preliminary study},
  journal = {European Journal of Pediatrics},
  year = {2026},
  doi = {10.1007/s00431-026-07566-2}
}
Kostenlos starten →